<VariationArchive VariationID="2426107" VariationName="NC_000002.11:g.(?_200173463)_(200320760_?)del" VariationType="Deletion" Accession="VCV002426107" Version="3" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-10" DateCreated="2023-02-13" MostRecentSubmission="2024-06-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1951510" VariationID="2426107">
      <GeneList>
        <Gene Symbol="SATB2" FullName="SATB homeobox 2" GeneID="23314" HGNC_ID="HGNC:21637" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>2q33.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="199269500" stop="199471266" display_start="199269500" display_stop="199471266" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="200134222" stop="200335988" display_start="200134222" display_stop="200335988" Strand="-" />
          </Location>
          <OMIM>608148</OMIM>
          <Haploinsufficiency last_evaluated="2020-07-15" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=SATB2">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-07-15" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=SATB2">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NC_000002.11:g.(?_200173463)_(200320760_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>2q33.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" innerStart="200173463" innerStop="200320760" display_start="200173463" display_stop="200320760" variantLength="147298" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.11" sequenceAccession="NC_000002" sequenceVersion="11" change="g.(?_200173463)_(200320760_?)del" Assembly="GRCh37">
            <Expression>NC_000002.11:g.(?_200173463)_(200320760_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000002.11:g.(?_200173463)_(200320760_?)del AND Chromosome 2q32-q33 deletion syndrome" Accession="RCV003119545" Version="3">
        <ClassifiedConditionList TraitSetID="10106">
          <ClassifiedCondition DB="MedGen" ID="C2676739">Chromosome 2q32-q33 deletion syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-05-25" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-05-25" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-02-13" MostRecentSubmission="2024-06-09">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">25885067</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="10106" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1446" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Glass syndrome</ElementValue>
                <XRef Type="Allelic variant" ID="608148.0002" DB="OMIM" />
                <XRef Type="Allelic variant" ID="608148.0003" DB="OMIM" />
                <XRef Type="Allelic variant" ID="608148.0001" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">2q33.1 deletion syndrome</ElementValue>
                <XRef ID="51" DB="Decipher" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Chromosome 2q32-q33 deletion syndrome</ElementValue>
                <XRef ID="MONDO:0012864" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">GLASS</ElementValue>
                <XRef Type="MIM" ID="612313" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">SATB2-associated syndrome (SAS) is a multisystem disorder characterized by significant neurodevelopmental compromise with limited to absent speech, behavioral issues, and craniofacial anomalies. All individuals described to date have manifest developmental delay / intellectual disability, with severe speech delay. Affected individuals often have hypotonia and feeding difficulties in infancy. Behavioral issues may include autistic features, hyperactivity, and aggressiveness. Craniofacial anomalies may include palatal abnormalities (cleft palate, high-arched palate, and bifid uvula), micrognathia, and abnormal shape or size of the upper central incisors. Less common features include skeletal anomalies (osteopenia, pectus deformities, kyphosis/lordosis, and scoliosis), growth restriction, strabismus/refractive errors, congenital heart defects, genitourinary anomalies, and epilepsy. While dysmorphic features have been described in individuals with this condition, these features are not typically distinctive enough to allow for a clinical diagnosis of SAS.</Attribute>
                <XRef ID="NBK458647" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="13206" />
                <XRef ID="13206" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="Decipher">
                <URL>https://decipher.sanger.ac.uk/syndrome/51</URL>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29023086</ID>
                <ID Source="BookShelf">NBK458647</ID>
              </Citation>
              <XRef ID="251019" DB="Orphanet" />
              <XRef ID="C2676739" DB="MedGen" />
              <XRef ID="MONDO:0012864" DB="MONDO" />
              <XRef Type="MIM" ID="612313" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="7075037" SubmissionDate="2024-06-04" DateLastUpdated="2024-06-09" DateCreated="2023-02-13">
        <ClinVarSubmissionID localKey="NM_015265.3_2_Deletion (exons 3-11)|MedGen:C2676739" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003793992" DateUpdated="2024-06-09" DateCreated="2023-02-13" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-05-25">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">25885067</ID>
          </Citation>
          <Comment>This variant is a gross deletion of the genomic region encompassing exon(s) 3-11 of the SATB2 gene, which includes the initiator codon. This deletion extends beyond the assayed region for this gene and therefore may encompass additional genes. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SATB2 are known to be pathogenic (PMID: 25885067). This variant has not been reported in the literature in individuals affected with SATB2-related conditions. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SATB2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000002.11:g.(?_200173463)_(200320760_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C2676739" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12699154</SubmissionName>
          <SubmissionName>SUB14505679</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7075037" TraitType="Disease" MappingType="XRef" MappingValue="C2676739" MappingRef="MedGen">
        <MedGen CUI="C2676739" Name="Chromosome 2q32-q33 deletion syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

